EU Panel Recommends Approval of Infusion Therapy for Pediatric MS
9 Articles
9 Articles
Rome, 21 Sep. (Adnkronos Salute) - The Committee for Medicinal Products for Human Use (Chmp) of the European Medicines Agency (Ema) recommended the approval of ocrelizumab for intravenous infusion for the treatment of children and adolescents with multiple sclerosis from 10 years of age and older, suffering from recurrent forms of multiple sclerosis (Smr). This is announced in a note, Roche pointing out that the final decision by the European Co…
EU panel recommends approval of infusion therapy for pediatric MS
Regulators in the European Union (EU) have recommended that the infusion therapy Ocrevus (ocrelizumab) be approved to treat children and teens, ages 10 and older, who have relapsing forms of multiple sclerosis (MS). The recommendation comes from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The CHMP’s […]
The Committee for Medicinal Products for Human Use (Chmp) of the European Medicines Agency (Ema) recommended the approval of ocrelizumab for intravenous infusion for the treatment of children and adolescents with multiple sclerosis from 10 years of age and older with relapsed forms of multiple sclerosis (Smr). Roche announces this in a note highlighting [...]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
